• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

硼替佐米用于预防和治疗致敏患者的排斥反应。

Use of bortezomib for prevention and treatment of rejection in sensitized patients.

作者信息

Hartono Choli, Lubetzky Michelle, Aull Meredith J, Saal Stuart, Figueiro Jose, Kapur Sandip, Dadhania Darshana

机构信息

Department of Transplantation Medicine, Weill Cornell Medical College/New York-Presbyterian Hospital, New York, New York, USA.

出版信息

Clin Transpl. 2009:499-503.

PMID:20524323
Abstract

We report 2 cases of sensitized patients who were successfully treated with bortezomib therapy resulting in reduction of donor-specific antibodies (DSA). Our cases illustrate the synergistic effects of combination therapy that includes bortezomib on prevention and treatment of AMR in highly sensitized patients. Moving forward, long-term data on sensitized patients treated with bortezomib are needed to fully evaluate the impact of this therapy.

摘要

我们报告了2例致敏患者,他们接受硼替佐米治疗后成功降低了供体特异性抗体(DSA)。我们的病例说明了包括硼替佐米在内的联合治疗对高致敏患者急性抗体介导排斥反应(AMR)预防和治疗的协同作用。展望未来,需要关于接受硼替佐米治疗的致敏患者的长期数据,以全面评估这种治疗的影响。

相似文献

1
Use of bortezomib for prevention and treatment of rejection in sensitized patients.硼替佐米用于预防和治疗致敏患者的排斥反应。
Clin Transpl. 2009:499-503.
2
Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.
Clin Transpl. 2009:455-9.
3
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.硼替佐米为抗体介导和细胞介导的急性排斥反应提供了有效的治疗方法。
Transplantation. 2008 Dec 27;86(12):1754-61. doi: 10.1097/TP.0b013e318190af83.
4
Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.基于蛋白酶体抑制剂的原发性抗体介导的肾移植排斥反应治疗。
Transplantation. 2010 Feb 15;89(3):277-84. doi: 10.1097/TP.0b013e3181c6ff8d.
5
Bortezomib rescue in refractory acute humoral rejection--report of a case.硼替佐米用于挽救难治性急性体液排斥反应——一例报告
Clin Transpl. 2009:431-2.
6
Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.在贝斯以色列女执事医疗中心(BIDMC),关于两名接受硼替佐米治疗抗体介导排斥反应患者的病例报告。
Clin Transpl. 2009:343-5.
7
Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.供者特异性抗人白细胞抗原抗体的肺移植:硼替佐米治疗在早期移植物功能障碍中的应用。
Ann Pharmacother. 2012 Jan;46(1):e2. doi: 10.1345/aph.1Q509. Epub 2011 Dec 27.
8
The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.硼替佐米对抗体介导排斥反应患者供体特异性抗体减少的影响
Clin Transpl. 2011:401-8.
9
Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.硼替佐米用于治疗初发性HLA抗体相关的抗体介导性排斥反应。
Clin Transpl. 2009:385-6.
10
Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.硼替佐米治疗抗体介导的排斥反应——3例报告
Clin Transpl. 2009:361-8.

引用本文的文献

1
Evaluating the Use of Bortezomib and Eculizumab in Desensitization of Transplant Patients.评估硼替佐米和依库珠单抗在移植患者脱敏治疗中的应用。
J Pharm Technol. 2014 Feb;30(1):31-38. doi: 10.1177/8755122513507430. Epub 2013 Nov 5.